TY - JOUR T1 - Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies JF - medRxiv DO - 10.1101/2022.07.22.22277927 SP - 2022.07.22.22277927 AU - Stephanie Vauleon AU - Katharina Schutz AU - Benoit Massonnet AU - Nanda Gruben AU - Marianne Manchester AU - Alessandra Buehler AU - Eginhard Schick AU - Lauren Boak AU - David J Hawellek Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/07/22/2022.07.22.22277927.abstract N2 - Background Huntington’s disease (HD) is caused by a cytosine adenine guanine-repeat expansion in the huntingtin gene. This results in the production of toxic mutant huntingtin protein (mHTT), which has an elongated polyglutamine (polyQ) stretch near the protein’s N-terminal end. The pharmacological lowering of mHTT expression in the brain targets the underlying driver of HD and is one of the principal therapeutic strategies being pursued to slow or stop disease progression. This report describes the characterisation and validation of an assay designed to quantify mHTT in the cerebrospinal fluid of individuals with HD, for use in registrational clinical trials.Methods The assay was optimised, and its performance was characterised with recombinant huntingtin protein (HTT) varying in overall and polyQ-repeat length.Results The assay was successfully validated by two independent laboratories in regulated bioanalytical environments and showed a steep signal increase as the polyQ stretch of recombinant HTTs pivoted from wild-type to mutant protein forms. Linear mixed effects modelling confirmed highly parallel dose-response curves for HTTs, with only a minor impact of individual slopes of the dose-response for different HTTs (typically <5% of the overall slope). This implies an equivalent quantitative signal behaviour for HTTs with differing polyQ-repeat lengths.Conclusion The reported method may be a reliable biomarker tool with relevance across the spectrum of HD mutations, which can facilitate the clinical development of HTT-lowering therapies in HD.Trial registration Not applicable.Funding F. Hoffmann-La Roche Ltd.Competing Interest StatementStephanie Vauleon, Katharina Schutz, Benoit Massonnet, Marianne Manchester, Alessandra Buehler, Eginhard Schick, Lauren Boak and David J Hawellek are employees of F. Hoffmann-La Roche Ltd. Nanda Gruben is an employee of ICON plc.Funding StatementThis study was funded by F. Hoffmann-La Roche Ltd. The OLE of the Phase I/IIa study of tominersen was initially sponsored by Ionis Pharmaceuticals, and transferred to F. Hoffmann-La Roche Ltd. The authors thank Shuang Song, of Chrysalis Medical Communications, UK, for providing editorial support for this manuscript, which was funded by F. Hoffmann-La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were obtained from the open-label extension (OLE) of the Phase I/IIa study of tominersen (NCT03342053). Statements on the ethical approval of the OLE study protocol are as follows: National Research Ethics Service (NRES) Committee of London - West London and GTAC, London, UK, gave ethical approval for this work; Ethik-Kommission of Medizinischen Fakultät der Universität Ulm, Germany, gave ethical approval for this work; Clinical Ethics Review Board of University of British Columbia, Canada, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request. ER -